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Abstract
Background: Increased concentrations of cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau, as well
as decreased amyloid-β 42 peptide, are biomarkers of Alzheimer’s disease (AD) pathology, but few studies have
shown an association with AD progression rate. We hypothesized that high CSF tau, as a marker of ongoing
neurodegeneration, would predict a more aggressive course of AD, using time to nursing home placement (NHP)
as the main outcome.
Methods: Our sample inlcuded 234 patients with mild cognitive impairment (MCI) due to AD (n = 134) or mild to
moderate AD (n = 100) who underwent lumbar puncture at a memory clinic and were followed for 2–11 years
(median 4.9 years).
Results: Individuals with CSF t-tau in the highest quartile (≥900 ng/L) had a higher ratio of NHP, both in the total
cohort and in patients with MCI only (adjusted HR 2.17 [95 % CI 1.24–3.80]; HR 2.37 [95 % CI 1.10–5.09], respectively),
than the lowest quartile. The association between high t-tau levels and future steep deterioration was confirmed in
analyses with conversion to moderate dementia (HR 1.66; 95 % CI 1.08–2.56), rapid decline in Mini Mental State
Examination score (≥4-point drop/12 months), and dying in severe dementia as outcomes.
Conclusions: To our knowledge, this is the first study to show that high CSF t-tau levels predict early NHP and
conversion to moderate dementia in an AD cohort. Selecting patients with high CSF t-tau, indicating more aggressive
neurodegeneration and steeper decline, for AD immunotherapy trials might increase the possibility of showing
contrast between active treatment and placebo.
Keywords: Nursing home placement, NHP, Alzheimer’s disease, CSF, Tau, p-tau, Amyloid-β, Rapid decline, Moderate
dementia, Death in severe dementia
Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder and the most common cause of dementia. It
is characterized by a gradual cognitive deterioration, loss
of function in activities of daily living (ADL), poor quality
of life, and shorter survival [1]. At the stage of mild cogni-
tive impairment (MCI), patients are still autonomous.
Subsequently, mild dementia is followed by moderate de-
mentia, defined as loss of ability to perform personal activ-
ities of daily living (PADL). Further disease progression
increases the burden on both patients and caregivers and
eventually leads to nursing home placement (NHP), with
a tremendous impact on societal costs [2]. The rate of
progression is highly variable between patients, sup-
posedly reflecting the intensity of the neurodegenerative
process [3, 4]. It is of utmost importance to learn more
about predictors of rapid decline in order to develop treat-
ment aimed at slowing down the disease process.
Aggregation of misfolded amyloid-β (Aβ) is an early
pathogenic event in AD. It is believed to mediate the
formation of abnormally phosphorylated tau in neurofib-
rillary tangles [5]. These two processes are reflected by
decreased amyloid-β 42 peptide (Aβ42) and increased
phosphorylated tau (p-tau) in the cerebrospinal fluid
(CSF) [6], while high CSF total tau (t-tau) is a marker
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of ongoing axonal degeneration [7, 8]. These three
biomarkers are predictors of conversion from the MCI
stage to AD mild dementia; that is, they separate MCI due
to AD from MCI non-AD cases on a group level [9, 10].
However, in patients with established AD, levels remain
stable from the prodromal/MCI stage onward [11].
Whether the magnitude of CSF t-tau may predict future
speed of progression later in AD is less well understood.
Recent findings suggest that tau pathology can propa-
gate between neurons [12, 13], and immunotherapy trials
targeting tau have recently started [14]. We previously
reported that high CSF tau can predict rapid cognitive
decline and risk of dying in patients with severe dementia
[15]. The aim of the present study was to investigate
whether high CSF tau levels also would predict time to
NHP. Factors known to promote early institutionalization,
such as single living, education level, and baseline severity of
cognitive impairment were taken into account. Further, we
analyzed whether high CSF tau was related to three other
proxies of progression rate: time to conversion to moderate
dementia, rapid cognitive decline as measured by repeated
evaluation with the Mini Mental State Examination (MMSE)
[16], and risk of dying in patients with severe dementia.
Methods
Study population and diagnostic procedures
We conducted a retrospective study, and the cohort
consisted of all patients referred to the Memory Clinic
at the Uppsala University Hospital, where all five authors
work as physicians. Participants underwent a lumbar
puncture (LP) as part of the diagnostic procedure
between 2003 and 2011 and were diagnosed with AD
(n = 234). Computed tomography or magnetic resonance
imaging scans, caregiver interviews, thorough cognitive
assessments, and in some cases regional glucose uptake by
positron emission tomography were other parts of the
diagnostic workup. The diagnosis of probable AD de-
mentia was set according to the National Institute of
Neurological and Communicative Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
criteria [17] and the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, criteria [18]. Patients
with neuroimaging findings suggesting a mixture of AD
and cerebrovascular pathology were not included.
CSF samples were collected by LP in polypropylene
tubes following standardized procedures. Samples with
clear visual blood contamination were excluded. All CSF
samples were centrifuged and aliquoted in polypropylene
tubes, and all samples were frozen once before analyses,
which were done continuously as part of routine clinical
practice. CSF concentrations of t-tau, p-tau, and Aβ42
were determined using sandwich enzyme-linked immuno-
sorbent assays (ELISAs) at the Clinical Neurochemistry
Laboratory, University of Gothenburg, Mölndal, Sweden
[8, 19, 20]. Assays were performed by experienced, board-
certified laboratory technicians strictly following proce-
dures approved by the Swedish Board for Accreditation
and Conformity Assessment. To reduce variability over
time and between batches, strict laboratory procedures
were followed, including regular calibration of pipettes
and preventive service of instruments (ELISA readers).
For each assay, specified acceptance criteria for the cali-
bration curve of an ELISA plate were applied for approval
of each individual run, including optical density (OD) of
the blank <0.1, OD of the highest calibrator between 1.2
and 3.0, OD of lowest calibrator larger than OD of the
blank, and coefficient of variance in percent below 15 %
for each calibrator (run in duplicate). In addition, internal
quality control (QC) samples consisting of aliquots of
pooled CSF (with low and high biomarker levels) were run
on each ELISA plate together with patient CSF samples.
The QC samples were placed at the beginning and the end
of each ELISA plate, and had to fall within a prespecified
target value set by repeated analyses for each ELISA format.
Last, to ensure conformance between ELISA batches, a
batch-bridging procedure to compare old with new batches
was performed using a panel of individual (n > 20) CSF
samples. If a systematic difference was identified, the new
batch was rejected and another batch was evaluated.
The CSF biomarker results were taken into account in
the diagnostic procedure, together with all other infor-
mation. Ninety-eight percent of the patients had at least
one CSF biomarker outside the normal range. The
original diagnoses were continuously reevaluated at
follow-up visits for a minimum of 2 years, and all diag-
nostic workup was scrutinized by one of the authors
(MDG) to ensure accuracy. Mild dementia was defined as
impaired performance in instrumental ADL only, and
moderate dementia was defined as loss of function in
PADL (i.e., needing assistance with either of grooming,
bathing, dressing, toileting, feeding, or ambulation). One
hundred patients fulfilled the AD dementia criteria at
baseline, and one hundred thirty-four individuals were at
the MCI stage [21] at baseline and converted to AD de-
mentia during follow-up. These 234 patients formed the
study population and were followed for a maximum of
11 years to May 2014 or to the date of death.
Outcomes
The digital medical record system kept at the Uppsala
County Council is common to all health care provided
in this area, including the vast majority of the general
practitioners (GPs) at the health centers and dementia
group living facilities, which enabled follow-up from
diagnosis to death. Most patients were followed at the
Memory Clinic every 6–12 months during the first years
after diagnosis, and they were subsequently followed at
health centers and eventually at the nursing homes.
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Dates of moving to a nursing home were captured from
the records, as were information on education level and
living conditions. Descriptions of the patients’ ADL func-
tion, cognitive deterioration, and medical status, as docu-
mented by the physicians at the Memory Clinic, by the
GPs, and in the nursing homes also by registered nurses
or occupational therapists, were collected from the med-
ical records. Date of conversion to moderate dementia
was defined as the date of the first documentation of im-
paired ability to perform PADL. Baseline MMSE scores
were retrieved from the testing that most closely corre-
sponded to the time of LP (within 1–3 months). Since this
was a clinical study, the intervals of the clinical follow-up
and MMSE retesting after baseline varied according to the
individual patient’s needs. Decline in MMSE was calcu-
lated as the difference between the baseline score and the
last available test score divided by time in months, and we
defined rapid cognitive decline as a ≥4-point decline in
MMSE per 12 months. Nine patients had a shorter time
span than 6 months between baseline and last MMSE.
Dying in severe dementia was identified as death after a
prolonged decline over months at the end stage of AD
and being immobilized and dependent in all PADL, in
contrast to premature death due to other causes.
Statistics
Cox proportional hazards models were used to assess the
HRs for NHP, conversion to moderate dementia, and dying
in severe dementia. Eight individuals lacked sufficient infor-
mation to determine cause of death and were censored as
nonresponders at the date of death. Another 11 patients
moved from Uppsala County Council and were censored as
nonresponders for conversion to moderate dementia/NHP
when they moved and as nonresponders at the date of
death. Patients lacking MMSE scores at follow-up (n = 21)
were withdrawn from the analyses of rapid decline. ORs of
rapid cognitive decline were determined by logistic regres-
sion. All analyses were performed in crude models and the
same multivariate models, adjusted for age, sex, living
condition, education level, baseline mild to moderate de-
mentia stage, and MMSE score. MCI was referenced when
the models were adjusted for mild to moderate dementia.
In addition, separate analyses were conducted with sub-
jects with baseline mild to moderate dementia and MCI
due to AD, respectively. The CSF biomarker levels in
univariate models and in stratified analyses (MCI and mild
to moderate dementia) for conversion from mild to mod-
erate dementia were entered with a split at median. In all
other analyses, the CSF biomarker levels were entered as
quartiles. Student’s t test was used for comparing normally
distributed variables between groups. The level of statis-
tical significance was set to p = 0.05. All statistics and fig-
ures were produced using Statistica version 10 software
(StatSoft, Tulsa, OK, USA).
Table 1 Description of the study population
Variable Data
n 234
Follow-up period, years, median (range) 4.9 (2–11)
Age, years, median (range) 70 (46–86)
MMSE score, mean ± SD 24 ± 5
Female sex 145 (62)
Coresidency status
Cohabiting (female/male) 99 (68)/79 (89)





CSF biomarkersa according to baseline AD stage, mean ± SD
t-tau, ng/L MCI 723 ± 354,
dementia 780 ± 558
p-tau, ng/L MCI 102 ± 43,
dementia 102 ± 48
Aβ42, ng/L MCI 351 ± 114,
dementia 374 ± 124
All three biomarkers normala 5 (2)
Low Aβ42, normal t-tau and p-tau 21 (9)
Low Aβ42, high t-tau or p-tau 48 (21)
Normal Aβ42, high t-tau and/or
p-tau
29 (12)
All three biomarkers pathological 131 (56)
Baseline AD stage, n (%); MMSE score, mean (SD)
MCI 134 (57); 26 ± 3
Mild dementia 85 (36); 22 ± 4
Moderate dementia 15 (7); 15 ± 6
NHP during follow-up 112 (48)
Males/females 34 (38)/78 (54)
MCI/dementia stage at baseline 54 (40)/58 (58)
Conversion to moderate dementia, n = 219 149 (68)
From MCI at baseline 83/134 (62)
From mild dementia at baseline 66/86 (77)
Rapid cognitive declineb 57 (24)
MCI 22 (16)
Mild to moderate dementia 35 (35)
Death during follow-up 83 (35)
Death in severe dementia during follow-up 46 (20)
MCI 19 (14)
Mild to moderate dementia 27 (27)
Aβ42 amyloid-β 42 peptide, AD Alzheimer’s disease, CSF cerebrospinal fluid,
MCI mild cognitive impairment, MMSE Mini Mental State Examination, NHP
nursing home placement, p-tau phosphorylated tau, t-tau total tau
Values are number (percent) unless otherwise stated
aReference values: Aβ42 >450 ng/L, t-tau <400 ng/L, p-tau <80 ng/L
b≥4-point decline in MMSE per 12 months
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Results
Baseline demographics and clinical characteristics are
shown in Table 1, and a flowchart is shown in Fig. 1. Con-
centrations of CSF biomarkers did not differ between the
disease stages. All but nine patients were treated with
cholinesterase inhibitors and/or memantine during part of
the follow-up period. Apolipoprotein E genotypes were
available for only 82 individuals (ε4/4, n = 25; ε4/3, n = 39;
ε4/2, n = 1; ε4 noncarriers, n = 17), who were therefore not
included in the analyses. During follow-up, 149 patients
converted to moderate dementia and 112 patients were ad-
mitted to NHP; all had converted to moderate dementia
before this event. The times from baseline to NHP (mean
± SD) were 4.3 ± 1.9 years in the MCI group (n = 54), 3.1
± 1.3 years in the mild dementia group (n = 46), and 1.3 ±
1.0 years in the moderate dementia group (n = 12).
Baseline CSF t-tau greater than the median value was
associated with a higher risk of NHP (Table 2), with a
dose-dependent relationship in crude and adjusted models
(Table 3, Fig. 2). Individuals in the highest quartile of CSF
t-tau (≥900 ng/L) experienced the highest risk, which
could also be seen when including subjects with MCI only
(adjusted HR 2.37, 95 % CI 1.10–5.09). The corresponding
risk for patients with baseline mild AD was HR 3.11 (95 %
CI 1.35–7.13) in crude analyses, which did not reach stat-
istical significance in the multivariate model. High p-tau
Fig. 1 Flowchart of the study population. CSF cerebrospinal fluid, AD Alzheimer’s disease, MCI mild cognitive impairment, NH nursing home,
NHP nursing home placement, NUD unspecified dementia
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or low Aβ42 concentrations were not associated with
NHP (Table 2, Additional file 1: Table S1, and Additional
file 2: Table S2).
Similarly, subjects in the highest quartile of t-tau had
higher rates of conversion to moderate dementia (Table 3,
Fig. 3). CSF t-tau above the median was associated with in-
creased rate of conversion to moderate dementia, both in
MCI (adjusted HR 1.66, 95 % CI 1.08–2.56) and in mild de-
mentia (adjusted HR 1.80, 95 % CI 1.02–3.20). These asso-
ciations remained in crude and multivariate models
including only cohabiting patients. There were no consist-
ent associations between CSF Aβ42 or p-tau concentrations
and this outcome in crude or adjusted models (Table 2,
Additional file 1: Table S1, and Additional file 2: Table S2).
Our previous findings in 196 subjects of this cohort,
followed for a shorter period [15], were confirmed in this
extended population. Setting the lowest quartile of CSF t-
tau as a reference, adjusted OR for rapid cognitive decline in
the highest quartile was 3.04 (95 % CI 1.16–8.99) (Table 3).
Using a cutoff of MMSE ≥3 points/year, the OR in patients
with CSF t-tau above the median was 2.76 (95 % CI 1.46–
5.21), MMSE ≥4 points/year was 2.87 (95 % CI 1.41–5.84),
and MMSE ≥5 points/year was 2.35 (95 % CI 1.15–4.80) in
the multivariate model. Patients in the highest t-tau quartile
also had a higher risk of dying in severe dementia (adjusted
HR 2.64, 95 % CI 1.10–6.33) (Table 3). Further, subjects in
the highest quartile of p-tau had an increased HR of death
in severe dementia compared with participants in the three
lowest quartiles (adjusted HR 1.88, 95 % CI 1.03–3.45);
otherwise, p-tau was not significantly related to these out-
comes (Additional file 1: Table S1). CSF Aβ42 was
associated with neither rapid cognitive decline nor death in
severe dementia (Additional file 2: Table S2). None of the
CSF biomarkers was related to all-cause mortality.
Discussion
To our knowledge, this is the first report that a high CSF
concentration of t-tau predicts an earlier need of
institutionalization (NHP) and conversion to moderate AD
dementia, two solid markers of disease burden and societal
costs. These associations were dose-dependent and present
already at the stage of MCI due to AD. Moreover, they were
independent of age, sex, education level, and living condi-
tions as well as of baseline cognitive and functional status.
We were able to capture these two outcomes in a memory
clinic cohort through a long follow-up with virtually no
loss. Further, subjects with AD who had high CSF t-tau had
a steeper cognitive decline and a higher risk of dying in
severe dementia, which confirms and expands previous re-
ports [15, 22, 23]. In our previous study [14], CSF levels of
p-tau were associated with an increased risk of rapid cog-
nitive decline. In the present study, CSF Aβ42 and p-tau
showed no consistent associations with the rate of decline.
Our results fit well with the current pathophysiological
model, where decreased Aβ42 in CSF reflecting amyloid
accumulation in the brain is a very early event, which is
stable from the presymptomatic stage onward [24]. The
density of amyloid plaques at autopsy is poorly cor-
related with clinical status, whereas there is a closer
correlation between the extent of tangles and cognitive
dysfunction [25, 26]. CSF t-tau and p-tau have been
shown to increase already in the asymptomatic stage or
Table 2 Cox proportional hazards ratios of nursing home placement, conversion to moderate dementia, and death in severe
dementia during follow-up and ORs of rapid cognitive decline in univariate analyses
Variable NHP (n = 112/234),
HR (95 % CI)
Conversion to moderate dementia
(n = 149/219), HR (95 % CI)
Rapid cognitive declinea
(n = 57/213), OR (95 % CI)
Death in severe dementia
(n = 46/234), HR (95 % CI)
Age (per year) 1.00 (0.97–1.03) 0.99 (0.96–1.01) 1.00 (0.95–1.04) 1.00 (0.96–1.04)
Male sex 0.56 (0.37– 0.83)b 0.93 (0.67– 1.52) 0.44 (0.22–0.89)b 0.65 (0.34–1.22)
Cohabiting 0.78 (0.52–1.18) 1.52 (1.01–2.30)b 1.37 (0.63–3.00) 1.10 (0.54–2.22)
Education level
≤7 years 1.00 1.00 1.00 1.00
8–12 years 0.74 (0.48–1.15) 0.98 (0.67–1.44) 2.03 (1.06–3.88)b 0.98 (0.51–1.89)
≥13 years 0.38 (0.22–0.65)b 0.76 (0.50–1.16) 0.43 (0.17–1.09) 0.27 (0.10–0.63)b
Mild to moderate dementia at
baseline
1.74 (1.20–2.53)b 1.71 (0.85–3.44) 2.99 (1.57–5.69)b 3.25 (1.80–5.86)b
MMSE at LP (per point) 0.86 (0.83–0.90)b 0.87 (0.87–0.91)b 0.95 (0.88–1.02) 0.89 (0.85–0.93)b
t-tau above median 1.81 (1.25–2.64)b 1.86 (1.35–2.58)b 2.56 (1.34–4.88)b 1.73 (0.95–3.17)
p-tau above median 1.12 (0.77–1.62) 1.35 (0.98–1.88) 1.63 (0.86–3.07) 1.26 (0.69–2.28)
Aβ42 below median 1.35 (0.93–1.97) 1.21 (0.88–1.67) 1.05 (0.56–1.97) 1.31 (0.76–2.37)
Aβ42 amyloid-β 42 peptide, LP lumbar puncture, MMSE Mini Mental State Examination, NHP nursing home placement, p-tau phosphorylated tau, t-tau total tau
a≥4-point decline in MMSE per 12 months
bp < 0.05
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Table 3 Crude and adjusted Cox proportional hazards ratios (95 % CI) of nursing home placement, conversion to moderate dementia, and death in severe dementia, with crude
and adjusted ORs (95 % CI) of rapid cognitive decline according to quartiles of cerebrospinal fluid total tau
CSF t-tau (ng/L) Nursing home placement (n = 112/234) Conversion to moderate dementia (n = 149/219) Rapid cognitive declinea (n = 57/213) Death in severe dementia (n = 46/234)
Crude Multivariateb Crude Multivariateb Crude Multivariateb Crude Multivariateb
≥900 2.61 (1.54–4.42)c 2.17 (1.24–3.80)c 2.51 (1.59–3.96)c 2.34 (1.45–3.77)c 2.91 (1.25–6.79)c 3.04 (1.16–8.99)c 2.94 (1.29–6.68)c 2.64 (1.10–6.33)c
681–899 1.79 (1.003–3.21)c 1.72 (0.94–3.14) 1.39 (0.86–2.23) 1.19 (0.72–1.96) 2.05 (0.80–5.26) 1.81 (0.66–4.94) 1.46 (0.56–3.78) 0.94 (0.30–2.90)
511–680 1.42 (0.80–2.51) 1.50 (0.82–2.75) 0.90 (0.56–1.47) 0.97 (0.59–1.59) 0.90 (0.34–2.42) 0.88 (0.30–2.55) 1.39 (0.54–3.61) 1.17 (0.42–3.30)
≤510 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
CSF cerebrospinal fluid
a≥4-point decline in Mini Mental State Examination score per 12 months



















in the MCI stage in both familiar and sporadic AD
[27, 28], and they remain constant thereafter [11].
CSF t-tau is classified as a marker of neuronal injury
in the National Institute on Aging-Alzheimer’s Associ-
ation criteria [29]. The magnitude of increase in CSF tau
levels is very high in disorders with malignant degener-
ation, such as Creutzfeldt-Jakob disease [30, 31]. However,
in pure tauopathies such as progressive supranuclear
paralysis and corticobasal degeneration, which generally
have a faster progression than AD, t-tau in CSF is only
moderately increased [32]. This suggests the existence of
specific mechanisms behind AD tauopathy. In addition to
a passive release from dying neurons, there is accumulat-
ing evidence that tau is actively secreted and transmitted
between synaptically connected neurons in a prion-like
manner [12, 13]. Hence, high CSF t-tau in AD may reflect
not only a high passive release of aggregated tau from
dying neurons but also a high fraction of “active” tau and
the intensity of AD spreading, which also adds support to
new therapeutic approaches acting in the extracellular
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Fig. 2 Cumulative HRs of nursing home placement by baseline levels of cerebrospinal fluid (CSF) total tau (t-tau) (highest quartile compared with
the lowest quartile)
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Fig. 3 Cumulative HRs of conversion to moderate dementia by baseline levels of cerebrospinal fluid (CSF) total tau (t-tau) (highest quartile compared
with the lowest quartile)
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space [33]. Our finding that high CSF t-tau, rather than
p-tau, is associated with AD progression rate is well in
concordance with this model.
One of the authors (LK) reviewed all published studies
(1756 in November 2015) resulting from a PubMed search
using the keywords “Alzheimer’s disease,” “cerebrospinal
fluid,” and “tau.” Similar to our findings, the vast majority
of the cross-sectional studies described no association
between tau levels and disease stage. Moreover, most lon-
gitudinal studies focused on distinguishing AD from non-
progressive AD (i.e., non-AD, cases in MCI populations),
where abnormal biomarkers, as expected, predict conver-
sion to AD. Regarding CSF biomarkers and progression in
the dementia stage of AD, we found seven longitudinal
studies, and the results were contradictory. Two studies
with a follow-up period of approximately 3 years showed
that high t-tau predicted steeper decline in MMSE score
[22, 23], but the results from the other five studies were
not clear-cut [34, 35] or negative [36–38], in this respect,
for patients with AD dementia. The association between
CSF biomarkers and loss of ADL has been assessed in two
reports from the Alzheimer’s Disease Neuroimaging Ini-
tiative cohort, with no clear evidence of any relation with
high CSF tau in patients who had reached the dementia
stage [39, 40]. No study had NHP or conversion to moder-
ate dementia as outcomes, which likely reflects the lack of
health care systems enabling long-term follow-up. Care-
giver burden, including loss of PADL and behavioral and
psychological symptoms of dementia (BPSD), underlie the
decision for NHP, as does the health of the spouse. In pa-
tients living alone, potential hazards, together with BPSD
and the quality of the home care, are important factors.
Interestingly, one report described a relationship between
high CSF tau and psychosis in AD [41].
Only a few studies have assessed the relationship with
AD mortality. In a small study, high CSF tau was associ-
ated with shorter 6-year survival [42]. Cluster analyses of
a larger cohort showed a relationship between very high
CSF t-tau and low Aβ42 and mortality [34]. In contrast,
high tau was associated with shorter survival in dementia
with Lewy bodies, but not in AD, in a cohort followed for
up to 7 years [43]. Mortality is not an ideal marker of
progression, since many patients have a “preterm” death
due to non-AD-related causes, which attenuates possible
relationships. In a recent study done in southern Sweden
with up to 12 years of follow-up [44], researchers found
no relationship between high t-tau and early death caused
by dementia. However, misdiagnosis cannot be excluded,
since data were collected from a registry. In the present
study, it was possible to capture “death in severe demen-
tia” by scrutinizing patients’ status through the medical
records.
CSF analyses have been a part of the diagnostic proce-
dures at Swedish memory clinics since the beginning of
the 2000s [2]. Forty percent of 17,000 newly diagnosed
patients in the National Swedish Dementia Registry
(SveDem; 2007–2011), where 92 % were assessed at a
specialist unit, underwent LP [45]. Our cohort is likely
to be representative of patients with AD in the younger
age group who consult memory clinics for diagnostic
workup. Further, the cohort is probably representative of
participants in AD clinical trials, who are recruited
mainly from a memory clinic, and a coliving spouse is
generally needed. However, it differs from a general AD
population with respect to younger age, higher educa-
tion (21 %, reflecting the setting in a university city), and
cohabiting status. Twenty-four percent were living alone,
which is less than in a general Swedish dementia popula-
tion, where 47 % live alone at the time of diagnosis (data
from SveDem, 50,000 patients, 2007–2015). Patients
with AD living together with a spouse are likely to be di-
agnosed at an earlier time point than those who live by
themselves. Since low education and solitary living are
factors associated with early NHP, our results would be
an underestimation of the true associations. NHP might
be a valid marker of rapid decline in our population,
since costs of nursing home care in Sweden are provided
by the authorities and are available regardless of income.
However, the timing of NHP differs between countries,
depending on ethnicity, social structure, and socioeco-
nomic status.
The major strength of this study is the long follow-up
period of a large AD cohort, where the diagnostic
workup was scrutinized and reevaluated. Virtually all
subjects had at least one positive CSF biomarker, and
loss to follow-up was minimal. We were able to capture
dates of NHP and the approximate time point for con-
version to moderate dementia, as well as to evaluate the
medical conditions at the time of death. This was pos-
sible because of the personal identity numbers assinged
to all Swedish citizens and the sharing of digital medical
records by all health care units, including the dementia
group living facilities. Another strength of the cohort is
the clinical setting at a memory clinic rather than a re-
search program with highly selected patients. Time to
NHP was chosen as a robust major outcome, and the
association between increased CSF t-tau and rapid de-
terioration was confirmed using three other outcomes
reflecting factors of vital importance for patients, care-
givers, and societal costs.
The present study also has limitations. One is the lack
of systematic follow-up at predefined time points for the
cognitive and functional assessments, as well as the lack
of formal ADL and BPSD scales. Instead, intervals varied
according to the individual patient’s needs; for example,
assessments of MMSE and ADL were more frequent in
rapid decliners. This would only create more contrast
between the groups, however.
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Conclusions
This study provides evidence of a biomarker that already
at the stage of MCI due to AD is a marker of future
deterioration rate. Our findings of an association be-
tween rapid decline and high CSF t-tau, rather than
Aβ42 or p-tau, are in accordance with the understanding
of tau as a marker of aggressive neurodegeneration, in-
cluding active interneuronal tau propagation. Further
prospective studies using standardized measurements
are needed to confirm the predictive value of t-tau in
CSF. During the past few years, research on AD bio-
markers has been focused on identifying preclinical cases
that may benefit from future disease-halting treatment.
However, clinical research ought to focus more on pa-
tients with rapid decline, in view of the very low quality of
life of patients and caregivers and the high societal costs.
Previous immunotherapy studies may have failed in part
due to misdiagnosis and/or slower than expected disease
progression in the highly selected participants. Clinical
trials evaluating the efficacy of potential AD disease-
modifying drugs should take into consideration the large
interindividual variation of progression rate and may bene-
fit from selecting participants with high CSF tau levels.
To our knowledge, this is the first study to show that
high CSF t-tau levels predict early NHP and conversion
to moderate dementia in an AD cohort. Selecting pa-
tients with high CSF t-tau, indicating a more aggressive
neurodegeneration and steeper decline, for AD immuno-
therapy trials might increase the possibility of showing
contrast between active treatment and placebo.
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